Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

MED23 (Q9ULK4) - Druggability - Molecular Target Synopsis

Chain-based assessment (last updated 10/09/2019)
Structural Druggability Help: Help

Chain-based assessment (last updated 10/09/2019)


Chains assessed1
Chains with at least one site assessed as druggable using the strict criteria1
Chains with at least one site assessed as druggable using the relaxed criteria1


		
PDB Chain Protein Name Druggable Relaxed Druggable Strict Details
6H02_A Mediator of RNA polymerase II transcription subunit 23 Yes Yes show/hide
Site num Site Status Pickpocket Polar Ratio Surfnet Gap Vertices Buried Surfnet Long Axis Druggable Relaxed Druggable Strict
1 empty 1.81 74.8 83.8 Yes Yes
2 empty 2.03 75.2 55.1 No No
3 empty 2.19 68.3 25.3 No No
4 empty 1.83 69.3 17.5 No No
5 empty 2.31 70.8 24.5 No No
6 empty 2.38 59.2 24.3 No No
7 empty 2.12 66.4 21 No No
8 empty 2.14 62.1 15.9 No No
9 empty 2.33 65.6 23 No No
10 empty 1.88 69.6 25.4 No No
Ligand-based Druggability Score: 0.35
Ligand-based Druggability Score Percentile: 83%
Ligand-based Druggability Help: Help




		
Number of proteins in the network : 13346


MED23 is involved in 14 interactions in the network.


Druggability
Overall Druggability Percentile: 44.87
Druggability for Cancer Therapeutics: 83.03
Druggability for Other Therapeutics: 37.24
Cancer-Associated
Cancer-associated percentile : 92.03
Network Articulation Point
Is MED23 critical for communication in the network?


Detailed Graph Legend:Help